So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

Eli Lilly Saudi Arabia and King Faisal Specialist Hospital & Research Centre (KFSHRC) have teamed up to make KFSHRC’s Neuroscience Centre a top regional hub for Alzheimer’s disease treatment.

A key regulatory committee sided against the drug this summer. But an appeal from Eisai appears to have worked, teeing ...

The memorandum of understanding (MOU) between the companies aims to advance the development of imaging agents used in PET scans.

I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...

BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

King Faisal Specialist Hospital & Research Centre (KFSHRC) and Eli Lilly Saudi ... MoU between KFSHRC & Lilly represents a transformative step in our fight against Alzheimer's disease.